Home

Although I’ve been a part of a number of successful drug launches at Incyte Corporation, DuPont and Merck, I’ve seen an even larger number of program failures. The Gliknik team is taking on immense challenges as it seeks to discover and develop drugs for immune disorders, and I believe they’ve got what it takes to succeed.

– Paul Friedman, M.D., Director
For me, it’s a matter of pride that important drugs from my labs have made it to the market and are being used so widely in combination therapy for HIV and more recently in Hepatitis C. I’m also proud to be on the Board of Gliknik, which I expect will generate significant new treatment options for people living with autoimmune diseases and cancers. I enjoy sharing what I have learned starting and selling several biotech companies.

– Raymond Schinazi, Ph.D., D.Sc., Gliknik Board Member
We have taken a bit of a different path than that taken by other companies – and it seems to be working. We are finding and advancing multiple drugs that may help a lot of people with cancers and autoimmune disorders.

– David Block, Gliknik Co-Founder & CEO

GL-2045 in Patients

GL-2045 is a recombinant Fc fusion protein in clinical trial which mimics the effects of the pooled human blood product IVIG in treating autoimmune disease. IVIG sells about $9 billion in autoimmune diseases annually, is approved for use clinically in numerous autoimmune diseases, and is in chronic short supply in every country. Gliknik retains full ownership of GL-2045.

Among the many potential advantages of GL-2045 over IVIg, convenient under-the-skin injection as a result of greater potency and far lower volume is expected to be associated with an improved safety and tolerability profile.

After 14 intravenous (IV) and subcutaneous (SC) cohorts in healthy participants in the US and Europe, Gliknik has advanced GL-2045 in patients, beginning with people with immune thrombocytopenia. No Adverse Events occurred at the highest SC dose tested in healthy participants.

Learn More About GL-2045 »

GL-0719 in Patients

GL-0719 is a recombinant Fc fusion protein in clinical trial designed to selectively inhibit the classical and lectin complement pathways, leaving intact the terminal complement pathway. GL-0719 is designed for treating autoimmune diseases caused by over-activation of the classical and lectin pathways. Gliknik retains full ownership of GL-0719.

After 7 intravenous and subcutaneous cohorts in healthy participants, GL-0719 began trials in patients with convenient under-the-skin dosing, beginning with people with Cold Agglutinin Disease. Initial results are very promising and dosing continues to assess safety, tolerability, and efficacy. GL-0719 has been very well tolerated with no drug-related Serious Adverse Events IV or SC in healthy participants or in patients.

Learn More About GL-0719 »

Our Approach

At Gliknik, our expertise is in modulation of the immune system and our mission is to discover and develop innovative biologics for people living with immune disorders.

Our determination to make a difference in the lives of individuals with autoimmune disease is evidenced by the assembly of talented scientists, augmented by our Board members, scientific advisors and a network of worldwide scientific and medical thought leaders.

Learn More About Our Approach »